# Title

 Food and Drugs. PART 331â€”ANTACID PRODUCTS FOR OVER-THE-COUNTER (OTC) HUMAN USE


# ID

 CFR-2018-title21-vol5.Pt. 331


# Structured Analysis Summary

| Type        | Values                                                                                                                                        |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['maximum', 'more than', 'before', 'equal to', 'minimum', 'at least', 'within']                                                               |
| Duration    | ['1.0 minute', '4.0 hour', '2.0 week', '24.0 hour', '60.0 year']                                                                              |
| Condition   | ['subject to', 'when', 'if']                                                                                                                  |
| Entities    | ['Aluminum', 'Scope', 'Bismuth', 'United States Pharmacopeia', 'Test', 'Antacid', 'Tartaric', 'Food', 'Indications', 'Indication', 'Glycine'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                            |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| within        | or more of the ingredients permitted in &#167;&#8201;331.11 within any maximum daily dosage limit established, each ingredient     |
| maximum       | of the ingredients permitted in &#167;&#8201;331.11 within any maximum daily dosage limit established, each ingredient is included |
| at least      | ingredient is included at a level that contributes at least 25 percent of the total acid neutralizing capacity                     |
| at least      | ingredient is included at a level that contributes at least 25 percent of the total acid neutralizing capacity                     |
| at least      | part of an antacid combination product and contributing at least 25 percent of the total acid neutralizing capacity;               |
| maximum       | 25 percent of the total acid neutralizing capacity; maximum  daily dosage limit is 8 grams.                                        |
| maximum       | (b) Bicarbonate-containing active ingredients: Bicarbonate ion;  maximum  daily dosage limit 200 mEq.                              |
| maximum       | Calcium-containing active ingredients: Calcium, as carbonate or phosphate; maximum  daily dosage limit 160 mEq.                    |
| maximum       | ingredients: Citrate ion, as citric acid or salt; maximum  daily dosage limit 8 grams.                                             |
| maximum       | (i) Phosphate-containing active ingredients:                                                                                       |
|               |               (1) Aluminum phosphate;  maximum  daily dosage limit 8 grams.                                                        |
| maximum       | (2) Mono or dibasic calcium salt;  maximum  daily dosage limit 2 grams.                                                            |
| maximum       | (3) Tricalcium phosphate;  maximum  daily dosage limit 24 grams.                                                                   |
| maximum       | used as a component of an effervescent preparation); maximum  daily dosage limit 200 mEq.                                          |
| maximum       | used as a component of an effervescent preparation); maximum  daily dosage limit 200 mEq.                                          |
| maximum       | Tartaric acid or its salts;  maximum  daily dosage limit 200 mEq.                                                                  |
| equal to      | accurately weighed amount of the antacid active ingredient equal to the amount present in a unit dose of                           |
| more than     | If wetting is desired, add not  more than 5 mL of alcohol (neutralized to an apparent                                              |
| more than     | (1) &#8220;Do not take  more than (maximum recommended daily dosage, broken down by age                                            |
| maximum       | (1) &#8220;Do not take more than ( maximum recommended daily dosage, broken down by age groups                                     |
| more than     | (1) &#8220;Do not take  more than (maximum recommended daily dosage, broken down by age                                            |
| maximum       | (1) &#8220;Do not take more than ( maximum recommended daily dosage, broken down by age groups                                     |
| maximum       | (1) &#8220;Do not take more than ( maximum recommended daily dosage, broken down by age groups                                     |
| more than     | (1) &#8220;Do not take  more than (maximum recommended daily dosage, broken down by age                                            |
| maximum       | (1) &#8220;Do not take more than ( maximum recommended daily dosage, broken down by age groups                                     |
| before        | the following statement &#8220;Ask a doctor or pharmacist before use if you are [bullet]&#8201;1 presently taking a                |
| minimum       | expressed in terms of the dosage recommended per minimum time interval or, if the labeling recommends more                         |
| more than     | minimum time interval or, if the labeling recommends more than one dosage, in terms of the minimum dosage                          |
| minimum       | expressed in terms of the dosage recommended per minimum time interval or, if the labeling recommends more                         |
| minimum       | expressed in terms of the dosage recommended per minimum time interval or, if the labeling recommends more                         |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60.0 year  | for persons up to 60 years old and 100 mEq.                                                                                                                                                                                                                                                                            |
| 60.0 year  | for persons 60 years or older.                                                                                                                                                                                                                                                                                         |
| 60.0 year  | of bicarbonate ion for persons up to 60 years old and 100 mEq.                                                                                                                                                                                                                                                         |
| 60.0 year  | of bicarbonate ion for persons 60 years or older.                                                                                                                                                                                                                                                                      |
| 60.0 year  | of sodium for persons up to 60 years old and 100 mEq.                                                                                                                                                                                                                                                                  |
| 60.0 year  | of sodium for persons 60 years or older, and 200 mEq.                                                                                                                                                                                                                                                                  |
| 60.0 year  | of bicarbonate ion for persons up to 60 years old and 100 mEq.                                                                                                                                                                                                                                                         |
| 60.0 year  | of bicarbonate ion for persons 60 years or older.                                                                                                                                                                                                                                                                      |
| 1.0 minute | for 1 minute.                                                                                                                                                                                                                                                                                                          |
| 24.0 hour  | (1) &#8220;Do not take more than (maximum recommended daily dosage, broken down by age groups if appropriate, expressed in units such as tablets or teaspoonfuls) in a 24-hour period, or use the maximum dosage of this product for more than 2 weeks, except under the advice and supervision of a physician.&#8221; |
|            |               (2) For products which cause constipation in 5 percent or more of persons who take the maximum recommended dosage: &#8220;May cause constipation.&#8221;                                                                                                                                                 |
|            |               (3) For products which cause laxation in 5 percent or more of persons who take the maximum recommended dosage: &#8220;May have laxative effect.&#8221;                                                                                                                                                   |
|            |               (4) For products containing more than 5 gm per day lactose in a maximum daily dosage: &#8220;Do not use this product except under advice and supervision of a physician if you are allergic to milk or milk products.&#8221;                                                                             |
|            |               (d) Drug interaction precaution.                                                                                                                                                                                                                                                                         |
| 2.0 week   | (1) &#8220;Do not take more than (maximum recommended daily dosage, broken down by age groups if appropriate, expressed in units such as tablets or teaspoonfuls) in a 24-hour period, or use the maximum dosage of this product for more than 2 weeks, except under the advice and supervision of a physician.&#8221; |
|            |               (2) For products which cause constipation in 5 percent or more of persons who take the maximum recommended dosage: &#8220;May cause constipation.&#8221;                                                                                                                                                 |
|            |               (3) For products which cause laxation in 5 percent or more of persons who take the maximum recommended dosage: &#8220;May have laxative effect.&#8221;                                                                                                                                                   |
|            |               (4) For products containing more than 5 gm per day lactose in a maximum daily dosage: &#8220;Do not use this product except under advice and supervision of a physician if you are allergic to milk or milk products.&#8221;                                                                             |
|            |               (d) Drug interaction precaution.                                                                                                                                                                                                                                                                         |
| 4.0 hour   | The labeling of the product contains the recommended dosage, under the heading &#8220;Directions&#8221;, per time interval (e.g., every 4 hours) or time period (e.g., 4 times a day) broken down by age groups if appropriate, followed by &#8220;or as directed by a physician.&#8221;                               |
|            |               (f) Exemption from the general accidental overdose warning.                                                                                                                                                                                                                                              |


## Condition

| Condition   | Context                                                                                                                                    |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------|
| if          | as safe and effective and is not misbranded if it meets each of the following conditions and                                               |
| when        | (4) Aluminum phosphate gel  when used as part of an antacid combination product                                                            |
| when        | Potassium-containing active ingredients: (1) Potassium bicarbonate (or carbonate when used as a component of an effervescent preparation); |
| when        | (1) Sodium bicarbonate (or carbonate  when used as a component of an effervescent preparation);                                            |
| if          | generally recognized as safe and effective analgesic ingredient(s), if it is indicated for use solely for the                              |
| if          | any generally recognized as safe and effective ant if latulent ingredient                                                                  |
| subject to  | All information submitted will be  subject to the disclosure rules in part 20 of this                                                      |
| if          | product contains the established name of the drug, if  any, and ident                                                                      |
| subject to  | used, as provided in &#167;&#8201;330.1(c)(2) of this chapter, subject to the provisions of section 502 of the act                         |
| if          | not rearranged to eliminate duplicative words or phrases if  the resulting warning is clear and understandable:                            |
| if          | recommended daily dosage, broken down by age groups if appropriate, expressed in units such as tablets or                                  |
| if          | recommended daily dosage, broken down by age groups if appropriate, expressed in units such as tablets or                                  |
| if          | statement &#8220;Ask a doctor or pharmacist before use if  you are [bullet]&#8201;1                                                        |
|             |                  presently taking a prescription drug.                                                                                     |
| if          | times a day) broken down by age groups if appropriate, followed by &#8220;or as directed by a                                              |
| if          | the dosage recommended per minimum time interval or, if the labeling recommends more than one dosage, in                                   |
| when        | deposited in bone, and dialysis osteomalacia may develop when large amounts of aluminum are ingested orally by                             |
| if          | antacids by normophosphatemic patients may result in hypophosphatemia if  phosphate intake is not adequate.                                |


## Entities

| Entities                   | Context                                                                                                                                      |
|:---------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                                             |
| Scope                      | Scope .                                                                                                                                      |
| Antacid                    | Antacid  active ingredients.                                                                                                                 |
| United States Pharmacopeia | as measured by the procedure provided in the United States Pharmacopeia  23/National Formulary 18.                                           |
| Bismuth                    | (c)  Bismuth -containing active ingredients:                                                                                                 |
|                            |               (1)                                                                                                                            |
| Bismuth                    | (2)  Bismuth  carbonate.                                                                                                                     |
| Bismuth                    | (3)  Bismuth  subcarbonate.                                                                                                                  |
| Bismuth                    | (4)  Bismuth  subgallate.                                                                                                                    |
| Bismuth                    | (5)  Bismuth  subnitrate.                                                                                                                    |
| Glycine                    | (f)  Glycine  (aminoacetic acid).                                                                                                            |
| Tartaric                   | Tartaric acid or its salts; maximum daily dosage limit                                                                                       |
| United States Pharmacopeia | sample according to the procedure provided in the United States Pharmacopeia 23/National Formulary 18 and calculate the percent contribution |
| Test                       | Test  modifications.                                                                                                                         |
| United States Pharmacopeia | certain products may require a modification of the United States Pharmacopeia  23/National Formulary 18 acid neutralizing capacity test.     |
| Indications                | of the product states, under the heading &#8220; Indications ,&#8221; the following: &#8220;For the relief of&#8221; (optional,              |
| United States Pharmacopeia | as calculated using the procedure set forth in United States Pharmacopeia 23/National Formulary 18 expressed in terms of the                 |
| Indication                 | containing basic aluminum carbonate gel identified in &#167;&#8201;331.11(a)(1)&#8212; Indication .                                          |
| Aluminum                   | Aluminum is not well removed by dialysis because it                                                                                          |


